04/17/2024
3:39 PM | Acrivon Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
04/15/2024
7:53 AM | Acrivon Therapeutics (Issuer)
EDELMAN JOSEPH (Reporting)
PERCEPTIVE ADVISORS LLC (Reporting)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
7:21 AM | Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G/A | |
04/11/2024
3:16 PM | Acrivon Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
04/09/2024
6:05 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/29/2024
8:06 AM | Acrivon Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/28/2024
7:00 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
|
03/28/2024
6:36 AM | Acrivon Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/06/2024
3:32 PM | Acrivon Therapeutics (Issuer)
Palani Santhosh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
7:15 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/16/2024
4:13 PM | Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:14 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
3:57 PM | Acrivon Therapeutics (Subject)
CITADEL ADVISORS LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
3:36 PM | Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
8:51 AM | Acrivon Therapeutics (Subject)
Marshall Wace North America L.P. (Filed by)
| Form SC 13G/A | |
02/13/2024
2:40 PM | Acrivon Therapeutics (Subject)
Sands Capital Ventures, LLC (Filed by)
| Form SC 13G/A | |
02/09/2024
3:37 PM | Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/09/2024
3:34 PM | Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
02/08/2024
7:27 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/19/2024
3:24 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/16/2024
3:45 PM | Acrivon Therapeutics (Issuer)
Cuillerot Jean-Marie (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/12/2024
3:46 PM | Acrivon Therapeutics (Issuer)
Cuillerot Jean-Marie (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/08/2024
6:28 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/17/2023
11:15 PM | Acrivon Therapeutics (Filer)
| Form EFFECT | |
12/08/2023
3:21 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/01/2023
3:35 PM | Acrivon Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:42 PM | Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:42 PM | Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:43 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/09/2023
8:12 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/09/2023
7:02 AM | Acrivon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/19/2023
6:45 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/28/2023
6:13 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/28/2023
6:17 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2023
4:23 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/23/2023
3:19 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/11/2023
7:25 AM | Acrivon Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
08/11/2023
6:11 AM | Acrivon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad) Big Banks have declared war on your wallet.
But it's not too late to fight back. Discover how to protect your assets from their latest maneuver. Learn More Now |
08/11/2023
6:17 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2023
3:58 PM | Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
06/28/2023
4:06 PM | Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2023
2:47 PM | Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/22/2023
4:02 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/20/2023
4:15 PM | Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2023
4:21 PM | Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2023
5:33 PM | Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/12/2023
11:20 AM | Acrivon Therapeutics (Subject)
Chione Ltd (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/05/2023
4:01 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/01/2023
7:40 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2023
7:05 AM | Acrivon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/09/2023
7:13 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/01/2023
11:25 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/01/2023
7:42 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/25/2023
10:27 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
